REPLIGEN CORP (RGEN)

Biological Products, (No Diagnostic Substances)

Latest Price

$174.73

TTM P/E

236.12

Normalized P/E

158.85

Div Yield

Book Value

37.46

P/B Ratio

4.66

Valuation metrics

EPS: $0.86

Book value / share: $37.39

Formula: √(22.5 × EPS × BVPS)

Graham Number

$26.90

85% downside

Norm. op. income: $55M (median of 7yr)

Tax rate: 18%

Discount rate: 10%

Growth assumption: zero (EPV is a no-growth value)

Earnings Power Value

$12.02

93% downside

Base FCF: $87M (median of recent 5yr)

Growth: 7%/yr (median YOY, capped at 25%)

Discount rate: 10%

Terminal growth: 3%

Projection horizon: 10 years

DCF Fair Value

$34.69

80% downside

EPS: $0.86

Target P/E: 15×

Formula: EPS × P/E

P/E Fair Value

$12.90

93% downside

100.0% held by institutions

Institution	Shares	Value	Ownership %	Change	Filing Date
BlackRock, Inc.	5.38M	$734.0M	9.54%	-608.1K	2026-06-30
FMR LLC	3.33M	$453.0M	5.90%	+439.9K	2026-06-30
UNITED CAPITAL FINANCIAL ADVISORS, LLC	2.79M	$380.0M	4.95%	+16.7K	2026-06-30
VANGUARD CAPITAL MANAGEMENT LLC	2.41M	$328.0M	4.27%	+14.7K	2026-06-30
VANGUARD PORTFOLIO MANAGEMENT LLC	2.31M	$315.0M	4.10%	+7.7K	2026-06-30
MAVERICK CAPITAL LTD	1.98M	$270.0M	3.52%	+465.7K	2026-06-30
STATE STREET CORP	1.80M	$245.0M	3.19%	+23.2K	2026-06-30
PRICE T ROWE ASSOCIATES INC /MD/	1.75M	$239.0M	3.11%	-3.13M	2026-06-30
MASSACHUSETTS FINANCIAL SERVICES CO /MA/	1.62M	$220.0M	2.87%	+219.5K	2026-06-30
WASATCH ADVISORS LP	1.59M	$216.0M	2.82%	+346.7K	2026-06-30